Comment on Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

Mutation-targeted personalised medicine for cystic fibrosis / C. Colombo. - In: THE LANCET RESPIRATORY MEDICINE. - ISSN 2213-2600. - 2:11(2014 Nov), pp. 863-865.

Mutation-targeted personalised medicine for cystic fibrosis

C. Colombo
Primo
2014

Abstract

Comment on Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
Settore MED/38 - Pediatria Generale e Specialistica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Colombo C Lancet Respir Med 2014.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 77.36 kB
Formato Adobe PDF
77.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/250226
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact